Is BEAT or LNSR more profitable?

LENSAR has a net margin of 57.57% compared to HeartBeam's net margin of 0.00%. LENSAR's return on equity of -529.08% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% LENSAR 57.57% -529.08% 50.03%

Is BEAT or ECOR more profitable?

HeartBeam has a net margin of 0.00% compared to electroCore's net margin of -39.96%. HeartBeam's return on equity of -686.78% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% electroCore -39.96% -1,956.38% -81.35%

Does the media refer more to BEAT or ECOR?

In the previous week, HeartBeam and HeartBeam both had 4 articles in the media. electroCore's average media sentiment score of 1.45 beat HeartBeam's score of -0.67 indicating that electroCore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative electroCore 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BEAT or NRXS?

NeurAxis has higher revenue and earnings than HeartBeam. NeurAxis is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartBeam N/A N/A -$21.01M -$0.51 N/A NeurAxis $5.32M 17.27 -$14.63M -$0.78 N/A

Is BEAT or NRXS more profitable?

HeartBeam has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% NeurAxis -492.76% N/A -641.25%

Does the media refer more to BEAT or NRXS?

In the previous week, HeartBeam had 3 more articles in the media than NeurAxis. MarketBeat recorded 4 mentions for HeartBeam and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.00 beat HeartBeam's score of -0.67 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HYPR or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% HeartBeam N/A -686.78% -348.65%

Does the media prefer HYPR or BEAT?

In the previous week, HeartBeam had 1 more articles in the media than Hyperfine. MarketBeat recorded 4 mentions for HeartBeam and 3 mentions for Hyperfine. Hyperfine's average media sentiment score of -0.02 beat HeartBeam's score of -0.67 indicating that Hyperfine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is BEAT or LUNG more profitable?

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% Pulmonx -55.03% -96.66% -38.32%

Does the media refer more to BEAT or LUNG?

In the previous week, HeartBeam had 2 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for HeartBeam and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.42 beat HeartBeam's score of -0.67 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Pulmonx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

HeartBeam (BEAT) Competitors

$0.39 -0.04 (-10.33%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.40 +0.01 (+3.63%)

As of 06:24 AM Eastern

Compare

BEAT vs. LNSR, ECOR, NRXS, HYPR, and LUNG

Should you buy HeartBeam stock or one of its competitors? HeartBeam's main competitors and comparable companies include LENSAR (LNSR), electroCore (ECOR), NeurAxis (NRXS), Hyperfine (HYPR), and Pulmonx (LUNG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartBeam compare to LENSAR?

HeartBeam (NASDAQ:BEAT) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LENSAR has a net margin of 57.57% compared to HeartBeam's net margin of 0.00%. LENSAR's return on equity of -529.08% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
LENSAR	57.57%	-529.08%	50.03%

HeartBeam presently has a consensus target price of $4.00, indicating a potential upside of 928.54%. LENSAR has a consensus target price of $11.50, indicating a potential upside of 60.84%. Given HeartBeam's stronger consensus rating and higher probable upside, equities analysts plainly believe HeartBeam is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

HeartBeam has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
LENSAR	$60.26M	1.46	-$34.28M	-$0.33	N/A

HeartBeam has a beta of -0.8, indicating that its stock price is 180% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, HeartBeam had 4 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for HeartBeam and 0 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 beat HeartBeam's score of -0.67 indicating that LENSAR is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartBeam	Negative
LENSAR	Neutral

Summary

LENSAR beats HeartBeam on 9 of the 16 factors compared between the two stocks.

How does HeartBeam compare to electroCore?

HeartBeam (NASDAQ:BEAT) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

HeartBeam currently has a consensus price target of $4.00, suggesting a potential upside of 928.54%. electroCore has a consensus price target of $18.00, suggesting a potential upside of 57.62%. Given HeartBeam's stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartBeam is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

electroCore has higher revenue and earnings than HeartBeam. electroCore is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
electroCore	$36.97M	2.79	-$13.97M	-$1.66	N/A

HeartBeam has a net margin of 0.00% compared to electroCore's net margin of -39.96%. HeartBeam's return on equity of -686.78% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
electroCore	-39.96%	-1,956.38%	-81.35%

HeartBeam has a beta of -0.8, indicating that its stock price is 180% less volatile than the broader market. Comparatively, electroCore has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 7.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, HeartBeam and HeartBeam both had 4 articles in the media. electroCore's average media sentiment score of 1.45 beat HeartBeam's score of -0.67 indicating that electroCore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
electroCore	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HeartBeam beats electroCore on 9 of the 15 factors compared between the two stocks.

How does HeartBeam compare to NeurAxis?

HeartBeam (NASDAQ:BEAT) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

HeartBeam has a beta of -0.8, indicating that its share price is 180% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

HeartBeam has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has higher revenue and earnings than HeartBeam. NeurAxis is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
NeurAxis	$5.32M	17.27	-$14.63M	-$0.78	N/A

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, HeartBeam had 3 more articles in the media than NeurAxis. MarketBeat recorded 4 mentions for HeartBeam and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.00 beat HeartBeam's score of -0.67 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 928.54%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 77.84%. Given HeartBeam's higher probable upside, research analysts clearly believe HeartBeam is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

HeartBeam and NeurAxis tied by winning 8 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
HeartBeam	N/A	-686.78%	-348.65%

Hyperfine presently has a consensus price target of $2.03, suggesting a potential upside of 157.38%. HeartBeam has a consensus price target of $4.00, suggesting a potential upside of 928.54%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

HeartBeam has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.35	-$35.57M	-$0.38	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hyperfine has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, meaning that its share price is 180% less volatile than the broader market.

In the previous week, HeartBeam had 1 more articles in the media than Hyperfine. MarketBeat recorded 4 mentions for HeartBeam and 3 mentions for Hyperfine. Hyperfine's average media sentiment score of -0.02 beat HeartBeam's score of -0.67 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Hyperfine and HeartBeam tied by winning 8 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Pulmonx?

HeartBeam (NASDAQ:BEAT) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
Pulmonx	-55.03%	-96.66%	-38.32%

HeartBeam has a beta of -0.8, suggesting that its share price is 180% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HeartBeam has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
Pulmonx	$87.44M	0.98	-$54M	-$1.16	N/A

In the previous week, HeartBeam had 2 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for HeartBeam and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.42 beat HeartBeam's score of -0.67 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Pulmonx	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam presently has a consensus price target of $4.00, suggesting a potential upside of 928.54%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 283.33%. Given HeartBeam's stronger consensus rating and higher possible upside, research analysts plainly believe HeartBeam is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

HeartBeam beats Pulmonx on 10 of the 16 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.44M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.76	25.26	274.08	25.69
Price / Sales	N/A	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	6.48	5.78	10.47	6.32
Net Income	-$21.01M	$151.55M	$3.49B	$359.73M
7 Day Performance	-7.34%	-0.01%	-0.67%	0.17%
1 Month Performance	-19.52%	-3.53%	-3.17%	-3.27%
1 Year Performance	-76.29%	6.37%	15.14%	5.58%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	3.0914 of 5 stars	$0.39 -10.3%	$4.00 +928.5%	-76.1%	$24.44M	N/A	N/A	1,700	News Coverage Analyst Downgrade Gap Down
LNSR LENSAR	2.6975 of 5 stars	$7.44 -2.7%	$11.50 +54.7%	-42.5%	$91.56M	$58.44M	N/A	150	Positive News
ECOR electroCore	3.1619 of 5 stars	$10.11 +0.5%	$18.00 +78.1%	+120.9%	$91.15M	$32.03M	N/A	83	Positive News Analyst Forecast Gap Down
NRXS NeurAxis	N/A	$7.08 +24.2%	$13.00 +83.6%	+172.8%	$88.91M	$5.32M	N/A	24	Positive News High Trading Volume
HYPR Hyperfine	2.1013 of 5 stars	$0.80 -0.4%	$2.03 +154.8%	-45.9%	$84.52M	$11.40M	N/A	102	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors